Skip to main content
OpenTrials
Completed

NCT Number: NCT04925700

The Oral Microbiome in OSCC

Previous work by a number of scientific teams has revealed that the types of bacteria that colonize the mouth differ between health and pre-cancerous or cancerous oral lesions. The purpose of this study is to investigate the extent of these changes and to correlate the changes with alterations in the activities of the host's own oral tissues. In doing so, we believe we can gain a better understanding of how particular bacterial species, or consortia of species, can result in an individual having an increased risk of the most common type of oral cancer -- oral squamous cell carcinoma. This knowledge may also lead to the identification of salivary biomarkers that can be used for clinical evaluation or screening. In addition, we seek to determine the extent to which a probiotic regimen can help prevent or rectify the disease-related changes in the types of bacterial colonizing the mouth. The microbiome in health, pre-cancerous lesions, and cancerous lesions will be determined from remnant microbial DNA in banked tissue samples. The effects of probiotics on the oral microbiome will be determined from DNA collected from swabs of oral tissue at baseline and then after 3 to 6 months of probiotic usage.

Completed

Looking for future studies?

Notify Me

Key information

Age range

21 year–89 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

University of Iowa College of Dentistry and Dental Clinics

Iowa City, Iowa, 52242, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Adults (21-70 years old) who have been diagnosed with oral dysplasia or that have been treatment-planned as wait and watch or
  • Adults (21-70 years old) or who have been diagnosed with oral squamous cell carcinoma, or matched healthy controls free of any oral lesions

Exclusion criteria

  • Adults who have had a course of antibiotics that was completed less than 3 months prior to the study;
  • Adults with any immunosuppressive condition or medication that would put the subject at risk of consuming daily probiotics;
  • Adults who regularly use probiotic dietary supplements
  • Adults that have alcohol/tobacco use history that does not match study population - this if for the healthy controls arm only.

Treatment and study plan

ProDentis Lozenge

Dietary Supplement

1-2 ProDentis Lozenges per day

Placebo Lozenge

Other

1-2 Placebo Lozenges per day

Primary outcomes

  1. Assessment of changes in the oral microbiome composition over time

    Time frame: Up to 3 months

    16S Genomic Profiling will be done in all recruited subjects via oral swab of pre-cancerous or cancerous oral lesion

  2. Determine the Effect of ProDentis on the Oral Microbiome

    Time frame: Up to 3 months

    Pre-Cancerous lesion is treatment planned as "watch-and-wait" or oral lesion is not present, recruited subjects will be randomly assigned to either the probiotic lozenge or placebo lozenge group.

Sponsors and collaborators

Lead sponsor

University of Iowa

Other

Registry information

Official study title

The Oral Microbiome in Oral Squamous Cell Carcinoma

Important dates

Study start
2022
Primary completion
2023
Study completion
2023
First posted
Jun 14, 2021
Registry last updated
Nov 18, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.